Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | BRAF |
Variant | S363F |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | BRAF S363F does not lie within any known functional domains of the Braf protein (UniProt.org). S363F has been identified in the scientific literature (PMID: 29903896), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Dec 2023). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF S363F |
Transcript | NM_004333.6 |
gDNA | chr7:g.140794360G>A |
cDNA | c.1088C>T |
Protein | p.S363F |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004333.5 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_001378471.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_047420768.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_017012559.2 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_017012559.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_017012558 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_001374244.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_047420767.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_001374258.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_001378469.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_017012559 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
XM_017012558.1 | chr7:g.140794360G>A | c.1088C>T | p.S363F | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF S363F BRAF K601E | melanoma | sensitive | Encorafenib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896). | 29903896 |
BRAF S363F BRAF K601E | melanoma | sensitive | Encorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Braftovi (encorafenib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896). | 29903896 |
BRAF S363F BRAF K601E | melanoma | sensitive | Dabrafenib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896). | 29903896 |
BRAF S363F BRAF K601E | melanoma | sensitive | Trametinib + Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896). | 29903896 |
BRAF S363F BRAF K601E | melanoma | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896). | 29903896 |
BRAF S363F BRAF K601E | melanoma | sensitive | Cobimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Cotellic (cobimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896). | 29903896 |
BRAF S363F BRAF K601E | melanoma | sensitive | Binimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mektovi (binimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896). | 29903896 |